Fonylin MR 60 mg

Cambodia • Ferron Par Pharmaceuticals


Non-insulin-dependent diabetes (type-2)
Non-insulin-dependent diabetes (type-2) in adults when dietary measures, physical exercise, and weight loss alone are not sufficient to control blood glucose.


Gliclazide 60 mg


3 strips of 10 sustained-release tablets

Dosage Forms

Sustained-release Tablet

ATC Classification



Not Recommended
This item should not be used with alcohol.
This item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.
Not Recommended
This item is not safe for use during pregnancy.
Not Recommended
This item is not safe for use during lactation.


Daily dose may vary from 30 to 120 mg taken orally in a single intake at breakfast time.

If a dose is forgotten, there must be no increase in the dose taken the next day.

As with any hypoglycemic agent, the dose should be adjusted according to patient metabolic responses (e.g. blood glucose, HbA1c).

Initial dose
The recommended starting dose of gliclazide is 30 mg daily. If blood glucose is effectively controlled, this dose may be used for maintenance treatment.

However, if the blood glucose is not adequately controlled, the dose may be increased to 60, 90, or 120 mg daily, in successive steps. The interval between each dose increment should be at least 1 month, except in patients whose blood glucose has not reduced after two weeks of treatment. In this case, an increase of the dose may be suggested at the end of the second week of treatment.

The maximum recommended daily dose is 120 mg. The breakability of the FONYLIN MR sustained release tablet enables flexibility of dosing to be achieved.